Binding Database

BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 2.8M data for 1.2M Compounds and 9.2K Targets. Of those, 1,346K data for 622K Compounds and 4.5K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Advanced Search

9 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID

Data

Article Title

Organization

Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.

Genentech

Quinofuracins A-E, produced by the fungus Staphylotrichum boninense PF1444, show p53-dependent growth suppression.

Institute Of Microbial Chemistry (Bikaken)

Discovery of NVP-BYL719 a potent and selective phosphatidylinositol-3 kinase alpha inhibitor selected for clinical evaluation.

Novartis Institutes For Biomedical Research

Structure-based design of novel inhibitors of the MDM2-p53 interaction.

Amgen

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.

Amgen

Small molecules that target protein misfolding.

Pfizer

Novel tertiary sulfonamides as potent anti-cancer agents.

Human Biomolecular Research Institute

Aminobenzothiazole derivatives stabilize the thermolabile p53 cancer mutant Y220C and show anticancer activity in p53-Y220C cell lines.

University Of Southampton

Discovery of CDZ173 (Leniolisib), Representing a Structurally Novel Class of PI3K Delta-Selective Inhibitors.

Novartis Institutes For Biomedical Research